LITHONATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lithonate, and when can generic versions of Lithonate launch?
Lithonate is a drug marketed by Solvay and is included in two NDAs.
The generic ingredient in LITHONATE is lithium citrate. There are two drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the lithium citrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lithonate
A generic version of LITHONATE was approved as lithium citrate by PAI HOLDINGS PHARM on May 21st, 1986.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for LITHONATE?
- What are the global sales for LITHONATE?
- What is Average Wholesale Price for LITHONATE?
Summary for LITHONATE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 4 |
| Clinical Trials: | 3 |
| Patent Applications: | 4 |
| DailyMed Link: | LITHONATE at DailyMed |
Recent Clinical Trials for LITHONATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Paolo Caimi, MD | Phase 1 |
| National Cancer Institute (NCI) | Phase 1 |
| Fred Hutchinson Cancer Research Center | N/A |
US Patents and Regulatory Information for LITHONATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Solvay | LITHONATE | lithium carbonate | CAPSULE;ORAL | 016782-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Solvay | LITHONATE | lithium citrate | SYRUP;ORAL | 017672-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |

